Andrew S. Grove, the 73-year-old former chief executive of Intel, is advocating a new master’s degree program in translational medicine (the art of taking laboratory, one-off discoveries and putting them into mass production — in higher volume and at lower cost than previous treatments).

The degree would combine the talents mainly of engineering and medical schools, with some business know-how tossed in.